A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
The first phase of a longitudinal multicenter study comparing bromocriptine and L-dopa (as Sinemet) as de novo therapy for Parkinson's disease using a double-blind randomized design has recently been completed. Over a period of 5.5 months, bromocriptine and L-dopa were equipotent in reducing functional and neurological disability. These observations complement and extend earlier studies and suggest a role for bromocriptine as de novo therapy of Parkinson's disease.
Riopelle
R J
RJ
Department of Neurology, Sunnybrook Medical Centre, Toronto, Ont., Canada.
Gawel
M J
MJ
Libman
I
I
King
D B
DB
McLean
D R
DR
Paulseth
R
R
Raphy
B
B
Bouchard
S
S
D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D011897:Random Allocation
D001971:Bromocriptine; D007980:Levodopa